APM vs CASI

For growth investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger pick with -15. 8% revenue growth year-over-year, versus -100. 0% for Aptorum Group Limited (APM). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Aptorum Group Limited (APM) delivered a total return of -96.

6%, compared to -99. 1% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: CASI returned -99. 0% versus APM's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.

(CASI) is the lower-risk stock at -0. 12β versus Aptorum Group Limited's 1. 60β — meaning APM is approximately -1402% more volatile than CASI relative to the S&P 500. On balance sheet safety, Aptorum Group Limited (APM) carries a lower debt/equity ratio of 28% versus 12% for CASI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CASI Pharmaceuticals, Inc.

(CASI) is pulling ahead at -15. 8% versus -100. 0% for Aptorum Group Limited (APM). On earnings-per-share growth, the picture is similar: Aptorum Group Limited grew EPS -25. 8% year-over-year, compared to -26. 7% for CASI Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CASI Pharmaceuticals, Inc.

(CASI) is the more profitable company, earning -137. 6% net margin versus -1644. 3% for Aptorum Group Limited — meaning it keeps -137. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CASI leads at -138. 8% versus -33. 5% for APM. At the gross margin level — before operating expenses — CASI leads at 39. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CASI (31.

1% yield) pays a dividend. APM does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 12), 31. 1% yield). Aptorum Group Limited (APM) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CASI: -99. 0%, APM: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: APM is a small-cap quality compounder stock; CASI is a small-cap income-oriented stock. CASI pays a dividend while APM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.